ISABEL ROSE: Open Payments
NPI 1316609548 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,717 in 142 payments from 40 companies in 2025. Trend: 2023 $2,202 · 2024 $5,909 · 2025 $3,717
Food & beverage: $3,717
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 18 | $372 |
| AstraZeneca Pharmaceuticals LP | 12 | $342 |
| PFIZER INC. | 13 | $319 |
| Janssen Biotech, Inc. | 10 | $309 |
| E.R. Squibb & Sons, L.L.C. | 5 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $144 |
| Gilead Sciences, Inc. | 2 | $133 |
| BeOne Medicines USA, Inc. | 5 | $125 |
| Immunocore Limited | 3 | $107 |
| Genentech USA, Inc. | 5 | $107 |
Products named: RYBREVANT, Trodelvy, ENHERTU, KIMMTRAK, JEMPERLI, ZYNLONTA, BESREMI, KISQALI.
Industry payments across MD — which companies pay providers there.
